Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 38-39, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2019.05.004
Keywords
Crohn's; Leukocyte trafficking; Integrins; Chemokines
Categories
Funding
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)
Ask authors/readers for more resources
The discovery of gut-specific leukocytes and the ability to modulate their function has been a ground-breaking development in the treatment of inflammatory bowel disease. Drugs target the interaction between lymphocytes and endothelial cells via integrins and their ligand cellular adhesion molecules. Safety, efficacy and sustainability of effect are key to this drug class, notwithstanding the association of natalizumab with fatal polyoma virus infection. Vedolizumab (2014) now licensed for the treatment of Crohn's disease around the world provides gut-specific immunosuppression. Targets for modulators of leukocyte trafficking include (examples in brackets) ICAM-1 (alicaforsen, efalizumab); MAdCAM-1 (PF-00547 659); alpha 4 and related receptors (abrilumab, etrolizumab, natalizumab, vedolizumab); chemokine receptor CCR9 (vercirnon); and sphingosine 1-phosphate receptors (etrasimod, fingolimod, ozanimod). Oral and subcutaneous therapies are in development. The safety, efficacy and practice points of licensed drugs are discussed, in addition to initial results from therapeutic trials. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available